<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Aliment. Pharmacol. Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2036</journal-id><journal-id journal-id-type="publisher-id">APT</journal-id><journal-title-group><journal-title>Alimentary Pharmacology &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0269-2813</issn><issn pub-type="epub">1365-2036</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7436383</article-id><article-id pub-id-type="doi">10.1111/apt.15940</article-id><article-id pub-id-type="publisher-id">APT15940</article-id><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Editors</subject></subj-group><subj-group subj-group-type="heading"><subject>Letters to the Editors</subject></subj-group></article-categories><title-group><article-title>Letter: is pneumococcal vaccination safe during the COVID&#x02010;19 pandemic? Authors&#x02019; reply</article-title><alt-title alt-title-type="left-running-head">LETTER TO THE EDITORS</alt-title></title-group><contrib-group><contrib id="apt15940-cr-0001" contrib-type="author"><name><surname>Al&#x02010;Ani</surname><given-names>Aysha H.</given-names></name><xref ref-type="aff" rid="apt15940-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt15940-cr-0002" contrib-type="author"><name><surname>Johnson</surname><given-names>Doug</given-names></name><xref ref-type="aff" rid="apt15940-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt15940-cr-0003" contrib-type="author" corresp="yes"><name><surname>Christensen</surname><given-names>Britt</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8746-4275</contrib-id><xref ref-type="aff" rid="apt15940-aff-0001">
<sup>1</sup>
</xref><address><email>britt.christensen@mh.org.au</email></address></contrib></contrib-group><aff id="apt15940-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>The Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><aff id="apt15940-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Victorian Infectious Diseases Unit</named-content>
<institution>The Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><pub-date pub-type="epub"><day>14</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><volume>52</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/apt.v52.5</issue-id><fpage>921</fpage><lpage>922</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 John Wiley &#x00026; Sons Ltd</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:APT-52-921.pdf"/><abstract abstract-type="short" id="apt15940-abs-0001"><p>
<bold>LINKED CONTENT</bold>
</p><p>This article is linked to Al&#x02010;Ani et al and Deniz et al papers. To view these articles, visit <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/apt.15779">https://doi.org/10.1111/apt.15779</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/apt.15903">https://doi.org/10.1111/apt.15903</ext-link>
</p></abstract><counts><fig-count count="0"/><table-count count="0"/><page-count count="2"/><word-count count="844"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.7 mode:remove_FC converted:19.08.2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="apt15940-body-0001"><p>We acknowledge the concern outlined by Deniz et al in regard to the possible detrimental effect of pneumococcal vaccination on a patient with probable or co&#x02010;existing COVID&#x02010;19 due to the potential for progression to cytokine storm, acute respiratory distress syndrome and death as a result of NLRP3 inflammasome activation and consequent hyperinflammatory response.<xref rid="apt15940-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> Triggering the NLRP3 inflammasome by intracellular viral pathogens may lead to excessive production of IL&#x02010;1&#x003b2; with potentially pathological consequences.<xref rid="apt15940-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> However, we wish to reiterate that our recommendations regarding pneumococcal vaccination for patients with IBD centre around optimising as many modifiable factors in patients who are likely to be, or due to be, immunocompromised.<xref rid="apt15940-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> This is especially important given that bacterial co&#x02010;infection, including <italic>Streptococcus pneumoniae</italic>, has been described in up to 50% of patients with COVID&#x02010;19 and has been associated with significantly reduced survival.<xref rid="apt15940-bib-0003" ref-type="ref">
<sup>3</sup>
</xref>, <xref rid="apt15940-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>
</p><p>Patients with IBD are at increased risk of vaccine&#x02010;preventable diseases.<xref rid="apt15940-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Current recommendations for patients with chronic inflammatory diseases maintained on immunosuppressive medications state that inactivated vaccines should be administered to this population.<xref rid="apt15940-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> In regard to pneumococcal vaccine, PCV13 (pneumococcal polysaccharide conjugated) should be administered to patients with chronic inflammatory conditions being treated with immunosuppression.<xref rid="apt15940-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> PPSV23 (pneumococcal purified capsular polysaccharides) should be administered to patients with planned commencement of low&#x02010; or high&#x02010;level immunosuppression.<xref rid="apt15940-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> It is the shared responsibility of the specialist and primary care provider to ensure that appropriate vaccinations are administered to immunocompromised patients as per current guidelines.<xref rid="apt15940-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> Vaccination should occur prior to planned immunosuppression where possible (<mml:math id="nlm-math-1"><mml:mo>&#x02265;</mml:mo></mml:math>4&#x000a0;weeks prior to immunosuppression for live vaccines) and should be avoided within 2&#x000a0;weeks of initiation of immunosuppression. Inactivated vaccines should be given <mml:math id="nlm-math-2"><mml:mo>&#x02265;</mml:mo></mml:math>2&#x000a0;weeks prior to immunosuppression.<xref rid="apt15940-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>
</p><p>While Deniz et al<xref rid="apt15940-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> refer to PPSV23 vaccination&#x02010;associated severe local and systemic reactions in patients with cryopyrin&#x02010;associated periodic syndromes, all these reactions resolved within 3&#x02010;17 days.<xref rid="apt15940-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="apt15940-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> More relevant to our IBD patient cohort is the finding in a recent systematic review for the European League Against Rheumatism 2019 recommendations, which demonstrated no overall safety issues independent of vaccine type from studies in rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy and primary systemic sclerosis.<xref rid="apt15940-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> These conditions more closely represent our IBD patient population and consequently reassure us of the safety of optimising vaccination status in this patient cohort. Furthermore, it is worth noting that, from an immunologic perspective, those on immunosuppressive or modulating medications may have lower immunogenic reactions and need additional doses of vaccine to overcome this.<xref rid="apt15940-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><p>Ultimately, preventing secondary co&#x02010;infection in patients with COVID&#x02010;19 may be associated with survival benefit and we therefore we stand by our recommendation of prophylactic pneumococcus vaccination in immunocompromised patients during the pandemic. However, in agreement with Deniz et al,<xref rid="apt15940-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> for those patients with active COVID&#x02010;19 infection, we advise against concurrent pneumococcal vaccination and suggest that patients should be pre&#x02010;screened for symptoms and exposure before vaccination occurs. In addition, clinicians should consider local rates of COVID&#x02010;19 transmission and refer to local guidelines for optimal timing of vaccination.</p></body><back><ack id="apt15940-sec-0002"><title>ACKNOWLEDGEMENTS</title><p>The authors' declaration of personal and funding interests are unchanged from those in the original article.<sup>2</sup>
</p></ack><ref-list content-type="cited-references" id="apt15940-bibl-0001"><title>REFERENCES</title><ref id="apt15940-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="apt15940-cit-0001">
<string-name>
<surname>Deniz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cagatay</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Gul</surname>
<given-names>A</given-names>
</string-name>. <article-title>Letter: is pneumococcal vaccination safe during COVID&#x02010;19 pandemic</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>. in press.</mixed-citation></ref><ref id="apt15940-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="apt15940-cit-0002">
<string-name>
<surname>Al&#x02010;Ani</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Prentice</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Rentsch</surname>
<given-names>CA</given-names>
</string-name>, et al. <article-title>Review article: prevention, diagnosis and management of COVID&#x02010;19 in the IBD patient</article-title>. <source xml:lang="en">Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>52</volume>:<fpage>54</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">32348598</pub-id></mixed-citation></ref><ref id="apt15940-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="apt15940-cit-0003">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID&#x02010;19 in Wuhan, China: a retrospective cohort study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="apt15940-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="apt15940-cit-0004">
<string-name>
<surname>Lai</surname>
<given-names>C&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C&#x02010;Y</given-names>
</string-name>, <string-name>
<surname>Hsueh</surname>
<given-names>P&#x02010;R</given-names>
</string-name>. <article-title>Co&#x02010;infections among patients with COVID&#x02010;19: The need for combination therapy with non&#x02010;anti&#x02010;SARS&#x02010;CoV&#x02010;2 agents?</article-title>
<source xml:lang="en">J Microbiol Immunol Infect</source>. <year>2020</year>. S1684&#x02010;1182(1620)30127&#x02010;30124.</mixed-citation></ref><ref id="apt15940-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="apt15940-cit-0005">
<string-name>
<surname>Rahier</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Magro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Abreu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Second European evidence&#x02010;based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease</article-title>. <source xml:lang="en">J Crohns Colitis</source>. <year>2014</year>;<volume>8</volume>:<fpage>443</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">24613021</pub-id></mixed-citation></ref><ref id="apt15940-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="apt15940-cit-0006">
<string-name>
<surname>Rubin</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ljungman</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>2013 IDSA clinical practice guideline for vaccination of the immunocompromised host</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2014</year>;<volume>58</volume>:e44&#x02013;100.</mixed-citation></ref><ref id="apt15940-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="apt15940-cit-0007">
<string-name>
<surname>Kuemmerle&#x02010;Deschner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rothenbacher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Tilson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hawkins</surname>
<given-names>P</given-names>
</string-name>. <article-title>&#x003b2;&#x02010;Confident&#x02010;registry: aiming to be largest&#x02010;ever studied cohort of cryopyrin&#x02010;associated periodic syndromes (CAPS) patients. Study design and baseline characteristics</article-title>. <source xml:lang="en">Pediatr Rheumatol Online J</source>. <year>2011</year>;<volume>9</volume>:<fpage>P16</fpage>.</mixed-citation></ref><ref id="apt15940-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="apt15940-cit-0008">
<string-name>
<surname>Walker</surname>
<given-names>UA</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kuemmerle&#x02010;Deschner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hawkins</surname>
<given-names>PN</given-names>
</string-name>. <article-title>Brief report: severe inflammation following vaccination against <italic>Streptococcus</italic>
<italic>pneumoniae</italic> in patients with cryopyrin&#x02010;associated periodic syndromes</article-title>. <source xml:lang="en">Arthritis Rheumatol</source>. <year>2016</year>;<volume>68</volume>:<fpage>516</fpage>&#x02013;<lpage>520</lpage>.<pub-id pub-id-type="pmid">26808830</pub-id></mixed-citation></ref><ref id="apt15940-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="apt15940-cit-0009">
<string-name>
<surname>Rondaan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Furer</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Heijstek</surname>
<given-names>MW</given-names>
</string-name>, et al. <article-title>Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations</article-title>. <source xml:lang="en">RMD Open</source>. <year>2019</year>;<volume>5</volume>:<elocation-id>e001035</elocation-id>.<pub-id pub-id-type="pmid">31565247</pub-id></mixed-citation></ref><ref id="apt15940-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="apt15940-cit-0010">
<string-name>
<surname>van Aalst</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Langedijk</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Spijker</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>de Bree</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Grobusch</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Goorhuis</surname>
<given-names>A</given-names>
</string-name>. <article-title>The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Vaccine</source>. <year>2018</year>;<volume>36</volume>:<fpage>5832</fpage>&#x02013;<lpage>5845</lpage>.<pub-id pub-id-type="pmid">30122649</pub-id></mixed-citation></ref></ref-list></back></article>